169 results

• Invokamet Approved For Use As Front-Line Diabetes Treatment, As Health Concerns Continue to Emerge

  May 26, 2016

  Irvin Jackson

  The FDA has approved Invokamet as a first-line diabetes drug despite growing concerns over diabetic ketoacidosis, kidney failure and potential amputation risks.

• Problems Combining Onglyza, Januvia With Sulphonylureas May Increase Risk Of Low Blood Sugar: Study

  May 13, 2016

  Irvin Jackson

  Combining Januvia and Onglyza with certain other diabetes drugs could result in dangerously low blood glucose levels, according to the findings of a new study.

• Heart Risks with Onglyza, Januvia Questioned By New Study

  May 2, 2016

  Irvin Jackson

  A new study failed to find any link between Onglyza, Januvia and similar diabetes drugs and an increased risk of heart failure.

• Heart Failure Risk with Onglyza, Similar Diabetes Drugs Lead to FDA Warnings

  April 6, 2016

  Austin Kirk

  Onglyza and similar diabetes drugs may increase the risk of heart failure, according to an FDA warning that will lead to new label warnings being added to the drugs.

• Invokana Study Claims Superiority over Januvia, Despite Ketoacidosis, Kidney Injury Risks

  March 21, 2016

  Irvin Jackson

  A new study indicates that Invokana is more effective than Januvia at helping to meet blood glucose goals, but the drug is plagued with concerns over diabetic ketoacidosis and kidney damage.

• Invokana Diabetic Ketoacidosis Guidelines Issued By European Agency Mirror Those By FDA

  February 17, 2016

  Irvin Jackson

  European drug regulators have issued recommendations calling for immediate treatment if signs of Invokana diabetic ketoacidosis are present, warning that they may go undetected.

• Diabetes Drug Pancreatic Cancer Lawsuits Dismissed on Preemption Grounds

  November 17, 2015

  Irvin Jackson

  A federal judge has granted summary judgment in the federal litigation over incretin mimetic diabetes drugs, which alleged that inadequate warnings were provided about the risk of pancreatic cancer from Byetta, Victoza, Januvia and Janumet.

• FDA Rejects Farxiga/Ongyza Combination Drug, Calls For More Clinical Trials

  October 21, 2015

  Irvin Jackson

  The FDA has rejected a combination drug involving Farxiga and Onglyza, ordering AstraZeneca to provide more clinical trial data.

• Invokana Diabetic Ketoacidosis (DKA) Side Effects Are Detectable, Preventable: Researchers

  September 9, 2015

  Austin Kirk

  Researchers say doctors can predict and prevent incidents of Invokana diabetic ketoacidosis through careful monitoring.

• Januvia Joint Pain Problems Result in FDA Warning for Class of Diabetes Drugs

  August 31, 2015

  Austin Kirk

  The FDA is warning that Januvia and similar diabetes drugs may be causing cases of severe joint pain among users.